There’s Still Time to Buy Gilead Sciences, Inc. (NASDAQ:GILD) Stock

In yesterday’s Wall Street session, Gilead Sciences, Inc. (NASDAQ:GILD) shares traded at $81.59, up 0.44% from the previous session.

32 analysts cover Gilead Sciences, Inc. (NASDAQ:GILD), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $116.00 and a low of $71.00, we find $90.05. Given the previous closing price of $81.23, this indicates a potential upside of 10.86 percent. GILD stock price is now 6.43% away from the 50-day moving average and 3.04% away from the 200-day moving average. The market capitalization of the company currently stands at $101.66B.

The stock has received a hold rating from 14 analysts and a buy rating from 15. Brokers who have rated the stock have averaged $90.44 as their price target over the next twelve months.

With the price target enhanced from $88 to $95, BofA Securities Upgraded its rating from Neutral to Buy for Gilead Sciences, Inc. (NASDAQ: GILD).

In other news, Dickinson Andrew D, Chief Financial Officer sold 5,000 shares of the company’s stock on Oct 17. The stock was sold for $400,017 at an average price of $80.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 104,003 shares in the company, valued at $8.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12, Chief Medical Officer Parsey Merdad sold 1,501 shares of the business’s stock. A total of $115,562 was realized by selling the stock at an average price of $76.99. This leaves the insider owning 70,130 shares of the company worth $5.72 million. Insiders disposed of 221,565 shares of company stock worth roughly $18.08 million over the past 1 year. A total of 0.08% of the company’s stock is owned by insiders.

On Friday morning Gilead Sciences, Inc. (NASDAQ: GILD) stock kicked off with the opening price of $82.00. During the past 12 months, Gilead Sciences, Inc. has had a low of $72.87 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.19, a current ratio of 1.02, and a quick ratio of 0.91. According to the stock market information, the enterprise value for the company is $120.24B, which is based on a 18.77 price-to-earnings ratio, a 4.34 price-to-earnings-growth ratio, and a beta of 0.34. The fifty day moving average price for GILD is $76.77 and a two-hundred day moving average price translates $79.17 for the stock.

The latest earnings results from Gilead Sciences, Inc. (NASDAQ: GILD) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.34, missing analysts’ expectations of $1.64 by -0.3. This compares to $0.90 EPS in the same period last year. The net profit margin was 20.15% and return on equity was 26.50% for GILD. The company reported revenue of $6.6 billion for the quarter, compared to $6.26 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.42 percent. For the current quarter, analysts expect GILD to generate $6.42B in revenue.

Gilead Sciences, Inc.(GILD) Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.

Related Posts